Added to YB: 2025-07-22
Pitch date: 2025-07-18
ABT [neutral]
Abbott Laboratories
+3.85%
current return
Author Info
A Peek Behind the Numbers is uncovering earnings manipulation and one-time benefits that Wall Street seldom talks about. Sign up for the newsletter.
Company Info
Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide.
Market Cap
$218.2B
Pitch Price
$123.71
Price Target
N/A
Dividend
1.88%
EV/EBITDA
18.47
P/E
15.76
EV/Sales
5.10
Sector
Health Care Equipment and Supplies
Category
N/A
Abbott’s (ABT) Q2 Setback- Were There Warning Signs?
ABT (earnings update): Stock fell 9% on 2025 revenue growth cut to 6-7% from 7.5-8.5%. Earnings quality concerns: Q1 DSOs up 4 days y/y ($450M potential impact), Q3 EPS guide below Street at $1.28-1.32. Non-GAAP EPS relies on adding back amortization, impairments. Watch rising receivables & declining stock comp (1.3¢ EPS benefit) in Q2.
Read full article (3 min)